Acute #eGFR Changes With #Finerenone Examined in a Prespecified Analysis of #FINEONE

#VisualAbstract by Cristina Popa

https://www.kireports.org/article/S2468-0249(26)03315-2/fulltext

Impact of #mGFR Versus #eGFR on the #Pharmacokinetics of a #Renally #Excreted Model #Drug in #Older Medical Patients: A Proof-of-Concept Trial

#VisualAbstract by @krishnadoctor1

https://www.kireports.org/article/S2468-0249(26)03252-3/fulltext

Findings from a randomized phase III #ClinicalTrial showed that mefatinib improved progression-free survival vs gefitinib, with a pronounced benefit in #EGFR L858R-mutated #NSCLC and comparable outcomes in exon 19 deletion.

#STTT #OpenAccess: doi.org/10.1038/s413...

How can #NSCLC escape #EGFR inhibition?

RAF1 amplification on extrachromosomal DNA reactivates MAPK signaling independently of EGFR, driving acquired erlotinib resistance and revealing a targetable mechanism.

#STTT #OpenAccess: doi.org/10.1038/s413...
#OncogeneAmplification #CancerGenomics

In the @nytimes.com, @danafarber.bsky.social research, led by Jaclyn LoPiccolo, MD, PhD, links a rare inherited #EGFR mutation to increased lung cancer risk, including never smokers. Read more: bit.ly/4rkGlfz

In a new study in @science.org, led by Dr. Jaclyn LoPiccolo of @danafarber.bsky.social, researchers report a rare #EGFR mutation linked to inherited lung cancer risk, especially among never-smokers.

➡️bit.ly/3VA6Wcw

リブロファズ®、EGFR阻害療法として4週に1回投与の新承認を取得 #東京都 #千代田区 #ヤンセンファーマ #eGFR #リブロファズ

リブロファズ®がEGFR陽性の非小細胞肺がんに対して4週に1回の投与方法で新たに承認されました。この革新的な治療法が患者の通院頻度を減少させることが期待されます。

Johnson & Johnson’s RYBREVANT Plus Chemo Pioneers Survival Gains in Lung Cancer #South_Korea #Seoul #Lung_Cancer #RYBREVANT #EGFR

SystImmune to Unveil Novel Data on Iza-bren at WCLC Congress 2026, Targeting Lung Cancer Treatment #United_States #SystImmune #Redmond #Iza-bren #EGFR-mutated

Why do #EGFR inhibitors stop working?
This single-cell study identifies an HSPA6–FOLR2 macrophage axis that drives osimertinib resistance in #LungCancer, highlighting CCL2 blockade as a promising combination strategy.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...

Shares in #China's #Hutchmed surged today after #GSK paid $110 million upfront for rights to a preclinical-stage #KRAS and #EGFR-targeted drug with potential in colorectal, pancreatic, and lung #cancer.

pharmaphorum.com/news/hutchme...